High-dose cyclophosphamide (HDC) is a chemotherapy treatment designed to eradicate autoreative B-and T-cells responsible for lymphocyte-mediated autoimmune illness while sparing the pluripotent blood stem cell of any ill effects. Multiple sclerosis (MS) is the most common inflammatory and demyelinating immune-mediated disorder of the central nervous system in young adults. Patients with moderate to severe, refractory MS, defined as an Expanded Disability Status Scale (EDSS) score of 3.5 or higher after two or more Food and Drug Administration-approved disease-modifying agents, received 200 mg/kg of cyclophosphamide over 4 days. For the next 2 years, quarterly EDSS score evaluations and biannual brain magnetic resonance imaging and neuro-ophthalmologic evaluations were obtained. Fifteen patients were evaluated for clinical response. During follow-up, one patient increased their baseline EDSS score by 1.0. EDSS score stability of decrease was realized in five of seven (71%) patients with relapsing-remitting MS and six of eight (75%) patients with secondary progressive MS. Four patients required additional immunomodulatory treatment after treatment. Treatment response was seen regardless of the baseline presence or absence of contrast lesion activity. HDC can effectively decrease symptoms, stop disease progression, and allow for disability regression in relapsing-remitting MS and secondary progressive MS patients. The most appropriate candidates for HDC, its duration of benefit, and the potential need for prophylactic preventative immune manipulation after HDC all require further investigation.
INTRODUCTION
Multiple sclerosis (MS) is the most common inflammatory and demyelinating disorder of the central nervous system in young adults. 1, 2 Within 15 years after disease onset, nearly half of those afflicted will require ambulatory aids, underscoring the disability produced by this immune-mediated disease. 3 Because no cure currently exists for MS, the contemporary goal of therapy is to change the short-term natural history of MS by decreasing relapse rates and postponing longterm disability. 4 However, despite the positive impact of disease-modifying treatment on relapsing-remitting multiple sclerosis (RRMS) activity, suboptimal responses and acute side-effect toxicities result in poor patient compliance. 5 Thus far, clinical trials have found limited to no effectiveness for secondary progressive multiple sclerosis (SPMS) treated. 4, 6, 7 In addition, to identify any clinical benefit in a prospective study limited to patients with severe, refractory RRMS is inherently difficult given that the distinction between RRMS and SPMS is vague because no reliable magnetic resonance imaging (MRI) scans or immunologic or serum markers reliably differentiate the two. 8 High-dose cyclophosphamide (HDC) is a chemotherapy treatment designed to eradicate autoreative B-and T-cells responsible for lymphocyte-mediated autoimmune illness while sparing the pluripotent blood stem cell of any ill effects. 9 HDC's efficacy, safety, and quality of life improvement are already established for a variety of lymphocyte-mediated autoimmune illnesses. [10] [11] [12] [13] [14] [15] [16] [17] In 2006, we reported preliminary results of the first 13 MS patients treated with HDC (investigational new drug No. 65863). 18 Recently, Krishnan et al 19 independently confirmed this work in a subset of MS patients with aggressive relapsing-remitting disease. The following describes the final 2-year follow-up for our initial cohort and two additional patients.
METHODS
All patients signed an informed consent approved by the internal review board of Stony Brook University, Stony Brook, NY. All patients met the diagnosis of MS as outlined by McDonald International Panel Diagnostic Criteria. 20 All patients required an Expanded Disability Status Scale (EDSS) score of 3.5 or higher with worsening disease status despite a minimum of two Food and Drug Administration-approved diseasemodifying therapies. For patients with relapsingremitting disease, worsening disease was defined as two or more relapses during the prior year. For patients with secondary progressive disease, worsening disease was defined as objective deterioration on neurologic examination during the prior year. All immunomodulatory therapies except for steroids were stopped 3 weeks before HDC treatment; given such active disease, a washout period was not ethical. All patients had a left ventricular ejection fraction of 45% or greater and a serum creatinine of 3 mg/dL or less.
Treatment methodology was fully delineated previously. 18 Patients received cyclophosphamide, 50 mg/kg/day, based on adjusted ideal body weight, over a 4-day period (investigational new drug No. 65863). Patients received hemorrhagic cystitis and antimicrobial prophylactics and, if required, blood transfusions. Filgrastim, started on the 10th day of hospitalization, was continued until the absolute neutrophil count rose to 1.0 x 109 /L for 2 consecutive days. No progenitor cells were infused to ensure marrow recovery. After HDC, patients received quarterly neurologic and biannual neuro-ophthalmic and brain MRI scan examinations for 2 years. The study's primary endpoint was to determine response rate of HDC in patients with moderate to severe, refractory MS. In conjunction with the Food and Drug Administration issuing an Investigational New Drug number, a sustained improvement was defined as a greater than a 6-month decrease of 1.0 or greater in EDSS score; disease progression was defined as a greater than a 6-month increase of 1.0 or greater in EDSS score; a MS disease flare was defined as any exacerbation requiring additional treatment.
RESULTS

Pretreatment evaluation
Patient characteristics and treatment histories are summarized in Table 1 . The 15 patients had a median age of 42.0 (range, 26-58) years, a median EDSS score of 6.5 (range, [4] [5] [6] [7] [8] , and a median disease duration of 8.6 (range, 3.1-29) years. Eight (53%) of the 15 patients had SPMS. Eight (53%) had previously received mitoxantrone hydrochloride. Twelve (80%) received active therapy 90 days before HDC evaluation. All patients had deterioration of their neurologic examination results during a 12-month period before the first HDC evaluation despite at least two standard MS disease-modifying therapies ( Table 2) .
Immediate chemotherapy effects
Patients experienced absolute neutropenia for a median of 9 (range, 6-13) days, received a median of 1.0 (range, 0-6) units of packed red blood cells, and received a median of 2.0 (range, 0-4) single unit donor platelet infusions. Patients tolerated the treatment well. Only expected toxicities were observed. Eight (53%) patients experienced and were treated for febrile neutropenia. Nausea controlled with antiemetics was common. Serum chemistry abnormalities were transient and corrected with fluids and electrolyte administration. Patient 14 contracted and was treated for E. coli bacteremia and C. difficile colitis.
Neurologic assessment
The median follow-up was 24 (range, 6-30) months. Patient 4 withdrew from all study evaluations after 9 Overall, during the follow-up period, seven (47%) patients met the study criteria for a sustained improvement, with a decrease of 1.0 or more in the EDSS scores (range of decrease, 1.0-6.0). More specifically, five (71%) patients in the RRMS cohort and two (25%) patients in the SPMS cohort enjoyed a sustained improvement. During the follow-up period, one patient (RRMS) met protocol criteria for disease progression defined as a greater than 6-month increase of 1.0 or more in EDSS score. The EDSS responses are shown by disease subset in Tables 3a and 3b .
During the 2-year follow-up, four patients had disease activity prompting additional treatment at a median of 19.5 (range, 19-22) months after HDC. Patient 8 (SPMS), whose EDSS had decreased by 2.5, developed an enhancing brain lesion found on routine scanning at 18 months. This imaging change was treated with pulse steroids. At 24 months, despite not having a documented 24-month EDSS follow-up, she was placed on standard remittive therapy. Patient 11 (RRMS) at 20 months experienced worsening balance and started to use a cane to avoid falling. She received pulse steroids followed by interferon subcutaneous beta-1b for 90 days through month 25; at 26 months, her EDSS was 1.0, and she has remained well and off therapy since (currently at 44 mo). Patient 13 (RRMS) at 22 months suffered double vision and was treated with steroids. The patient's primary neurologist, 2 weeks before her 2-year follow-up, despite no new Subset analysis of the EDSS score revealed improvement in two general areas: (1) ambulation (the major determinant of the EDSS score), six patients improved to full ambulatory status (EDSS 4.0 or less: walking without aid or rest some 500 meters); and (2) urinary function, six patients experienced full resolution of urinary symptoms.
Radiographic assessment
The MRI scan results are provided in Table 4 . All of the patients had abnormal baseline brain MRI scan results consistent with MS. 21 Thirteen patients had imaging studies centrally reviewed, allowing for a more precise evaluation of nonenhancing lesions. Eleven (85%) patients had 15 or more nonenhancing lesions. During the follow-up period, three patients had a change in the number of measurable nonenhancing lesions. Three (23%) patients with RRMS had baseline enhancing lesions, including patient 13 with 14 enhancing lesions. At 12 months, patient 5 showed one new enhancing lesion without a corresponding high-intensity, T2wieghted fluid-attenuated inversion recovery signal; this lesion spontaneously resolved by her scheduled 18-month study. Patient 8 (RRMS), at 18 months, developed new enhancing lesions.
Neuro-ophthalmic assessment
No patient during the follow-up period experienced optic neuritis. Many patients' visual acuity and color perception improved as measured by Snell eye chart examination and by American Optical Hardy-Rand-Rittler pseudoisochromatic plates, as shown by patient 7, whose visual acuity improved from 20/60 OD and 20/50 OS to 20/20 OU, and patient 1, whose color perception improved by more than three pseudoisochromatic plates. However, given the sample size, no statistical improvement in visual acuity or color perception was found (data not shown).
Overall efficacy
In this study, 15 patients completed HDC and were assessed for disease response. Five of seven (71%) patients treated with HDC for moderate to severe, refractory RRMS had either stable disease or a sustained improvement at 2 years. Despite a motivated population of individuals, two patients with SPMS were lost to long-term follow. We, therefore, conservatively conclude that six of eight (75%) patients treated for moderate to severe, refractory SPMS had either stable disease or a sustained improvement at 2 years (Table 5 ).
DISCUSSION
HDC is a 4-day infusion therapy designed to eliminate autoreactive lymphocytes. Moreover, we have previously shown that HDC, in vivo, preferentially targets naive T (CD45/CD4/RA+)-cells in RRMS and SPMS patients, the T-cell compartment that may be the source of these autoreactive lymphocytes. 22 The clinical goal of this 2-year, phase II study was to halt disease progression without additional remittive Table 3b . Expanded disability severity scores for secondary progressive participants: initial compared with last follow-up. therapy as measured by the EDSS score. The EDSS score is rated from 0 (normal neurologic examination) to 10 (death caused by MS). To appreciate the observation of EDSS reduction seen in our cohort, it is important to recall that MS progression is independent of presentation once an EDSS score of 4.0 is reached 23 and that SPMS is often characterized by irreversible disability. 24 All of the patients enrolled in this trial had moderate to severe, refractory MS with a median EDSS score of 6.5. This EDSS score is characterized by constant bilateral assistance (canes, crutches, or braces) needed for the patient to walk about 20 m without resting. All had active disease progression before HDC despite multiple aggressive interventions. Eight patients suffered from SPMS. Given the progressive natural history of MS, disability progression during the 2-year followup was sadly anticipated. 25 Despite these negative predictors, after HDC, only a single patient met study criteria for disease progression. Further, and unexpectedly, seven (47%) exhibited a decrease of 1 or greater in their EDSS score. Importantly and in distinction to other MS therapies, the EDSS score reduction was not limited to RRMS patients but also occurred in SPMS patients. Taken together, disease stability or EDSS improvement occurred in 71% of the RRMS patients and occurred in 75% of the SPMS patients.
Four patients, despite having stable or an improved EDSS score after HDC, were treated for documented disease activity. Disease exacerbation after HDC does not equate to complete loss of benefit. We previously reported patients with severe, refractory myasthenia gravis treated with HDC to have measurable but decreasing disease activity, even 52 weeks after treatment. 12 In addition, the positive effects of HDC can be underestimated by the EDSS score because a disability score does not measure functionality. 26 Patient 6 with SPMS had a stable EDSS score, yet her pyramidal and cerebellar subscores at 2 years increased. However, before HDC, she suffered severe debilitating headaches, which resolved. She had suffered from poor diction and pressured speech; at 24 months, she spoke more clearly with unpressured speech, and a sense of dizziness that plagued her before the HDC had totally dissipated. Likewise, patient 7 with SPMS, who had an increase in her pyramidal score (which occurred at the first follow-up at 3 mo), reported at 25 months that she could go out to dinner with her husband and navigate through the restaurants and was now able to shower by herself. The observations and findings made in this study are not negated by its small size. The patient population enrolled and treatment rendered were uniform. Moreover, although HDC is novel in its application to treat MS, it is not novel in the treatment of other lymphocyte-mediated autoimmune illnesses. It is fit and proper to combine these salutatory HDC outcomes with other HDC published reports, as seen in the treatment of chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, aplastic anemia, multifocal motor neuropathy, systemic lupus erythematosus, and scleroderma. 10, 12, [14] [15] [16] 27 In each of these illnesses, HDC's efficacy was demonstrated. Therefore, given the high response rate of HDC for the treatment of other autoimmune illness, it is unfounded to conclude that 11 of 15 (73%) of the MS patients enrolled in this study had a coincidental, spontaneous, 2-year sustained response immediately after therapy.
HDC can effectively decrease symptoms, stop disease progression, and allow for disability regression in RRMS and SPMS patients. The most appropriate candidates for HDC, its duration of benefit, and the potential need for prophylactic, preventative immune manipulation after HDC require further investigation.
